What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The GLISTEN trial provides high-quality randomized evidence of incremental efficacy versus placebo with a statistically significant difference in itch score. However, the magnitude of the effect is modest, and there is no evidence of superiority over active standard-of-care treatments.
Does the economic case hold at the expected price? — Cost effectiveness
No peer-reviewed cost-utility analysis, QALY estimate, or ICER for linerixibat was identified. Therefore, cost-effectiveness cannot be assessed.
Is there quality-of-life evidence payers weigh? — Quality of life
The trial demonstrated statistically significant improvements in itch-related sleep interference. However, no treatment-specific EQ-5D utility gain or QALY-ready incremental utility estimate was identified.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Diarrhea occurred in 62% of patients, with other adverse events leading to a higher discontinuation rate compared to placebo. The safety profile is concerning due to frequent gastrointestinal adverse effects.
Was the drug compared against what payers expect? — Comparator Selection
The trial used placebo rather than an active comparator, which limits the ability to assess comparative efficacy against standard-of-care treatments.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population was representative of adults with moderate-to-severe PBC-associated pruritus, but there are gaps in subgroup analyses and representativeness for excluded populations.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Linerixibat does not require new diagnostic tests and fits into existing care pathways, but requires monitoring for liver tests and vitamin deficiencies.
Are the wider system costs understood? — Resource Use and Cost Implications
No budget-impact or resource information is presented, and no direct medical costs or cost savings from avoided events are reported.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on a single pivotal phase 3 trial with limitations in long-term data and lack of independent replication. The overall clinical evidence body was judged low certainty by the 2026 draft AGA/AASLD GRADE assessment.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There is high uncertainty regarding the long-term effect, comparative efficacy, and economic value. No economic sensitivity analysis can be evaluated due to the absence of a public ICER model.
